Extract

This study is designed to evaluate the safety and beneficial effects of NBI-56418 compared to placebo and leuprorelin (an approved endometriosis therapy) over a three month period followed by an additional three months of treatment on NBI-56418.

Inclusion criteria

• Endometriosis

Country

• Bulgaria
• Hungary
• Poland
• Romania
• Russian Federation
• Ukraine

Links

• ictrp
• nct